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Aim: To investigate circulating visfatin and vaspin levels in first-degree relatives of subjects
with type 2 diabetes mellitus (FDRs) who frequently have higher value of HOMA-IR and beta
cell dysfunction.
Methods: Serum visfatin and vaspin concentrations were measured in 179 Iranian subjects
(90 normoglycemic FDRs and 89 age- and sex-matched healthy controls) using enzyme-
linked immunosorbent assay (ELISA) methods.
Result: Serum visfatin levels were significantly lower in the FDRs when compared to the
controls (1.71  0.93 ng/ml versus 2.69  2.02 ng/ml, p = 0.0001). However, no significant
difference was found in serum vaspin concentrations between the FDRs and the controls
(0.452  0.254 ng/ml versus 0.409  0.275 ng/ml, p > 0.05). In multiple logistic regression
analysis, the FDRs showed a significant association with lower visfatin levels after adjust-
ments for age, sex, Body Mass Index, systolic and diastolic blood pressures, lipid profile,
blood glucose levels and HOMA-IR [odds ratios (OR) = 1.71, 95% confidence interval
(1.30–2.25); p < 0.0001].
Conclusion: The FDRs showed a significant association with lower visfatin levels. The
observed lower circulating visfatin levels in FDRs may suggest a pathophysiological role
for visfatin in beta cell dysfunction in this group.
# 2011 Elsevier Ireland Ltd. All rights reserved.
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Since the mid-1990s, several adipocytokines have been
identified in relation to obesity and comorbidities, type 2
diabetes mellitus and its complications, metabolic syndrome,
immunity, neuroendocrine, and cardiovascular functions
[1–3]. The growing number of adipocyte-derived, cytokine-
like hormones includes novel insulin resistance inducers and
insulin-mimetic/insulin-sensitizer molecules such as adipo-
nectin, leptin, visfatin, and vaspin.* Corresponding author. Tel.: +98 7712541827; fax: +98 7712541828.
E-mail address: inabipour@gmail.com (I. Nabipour).
0168-8227/$ – see front matter # 2011 Elsevier Ireland Ltd. All rights 
doi:10.1016/j.diabres.2011.10.004Visfatin, which is identical to the ‘‘pre-B cell-colony
enhancing factor’’ and ‘‘nicotinamide phosphoribosyltrans-
ferase,’’ is secreted abundantly by the visceral fat of humans
and mice and mimics the action of insulin [4]. Further, in vitro
studies showed that glucose signaling for visfatin release in
adipocytes involves the phosphatidylinositol 3-kinase (PI3-
kinase) and protein kinase B pathway [5] and the regulation of
glucose uptake by visfatin in human osteoblasts involves
insulin receptor phosphorylation [6]. Although current data
may suggest that insulin and visfatin act in concert to lowerreserved.
Table 1 – The general characteristics, including blood
pressure and anthropometric measurements, and the
biochemical parameters of first-degree relatives of sub-
jects with type 2 diabetes mellitus (FDRs) and healthy
controls.
FDRs (n = 90) Control (n = 89)
Female/male ratio 49/41 40/49
Age (years) 40.55  9.63 41.37  9.47
Systolic BP (mmHg) 115.0  13.8 115.82  12.84
Diastolic BP (mmHg) 74.72  9.95 74.45  10.47
Height (cm) 165.88  9.31 166.89  8.87
Weight (kg) 75.92  13.43 74.32  14.75
Waist circumference (cm) 94.41  10.19 93.10  12.63
Hip circumference (cm) 104.76  9.975 102.93  12.42
WHR 0.90  0.14 0.91  0.17
BMI (kg/m2) 27.57  4.25 26.52  4.24
Fasting glucose (mg/dl) 80.5  8.56 79.77  10.46
2 h-OGTT (mg/dl) 92.17  15.68 92.03  16.65
Total cholesterol (mg/dl) 198.54  36.85 196.92  37.24
Triglyceride (mg/dl) 168.51  82.3 155.71  75.0
HDL-cholesterol (mg/dl) 43  10.38 45.44  11.65
LDL-cholesterol (mg/dl) 121.01  31.55 120.04  32.44
Insulin (mIU/ml) 8.75 (5.25–16.68) 6.56 (5.03–10.18)*
HOMA-IR 1.82 (1.05–3.06) 1.29 (0.98–1.93)*
BMI, Body Mass Index; WHR, waist to hip ratio; BP, Blood Pressure;
2 h-OGTT, second-hour oral glucose tolerance test; HOMA-IR,
homeostasis model of assessment index.
Data are means (SD), except for insulin and HOMA-IR [medians
(interquartile ranges)].
* p values <0.05 (the FDRs in comparison to the controls).
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conflicting results regarding associations between visfatin and
insulin-mimetic effect, insulin resistance, beta cell function
impairment, adiposity, subcutaneous versus visceral fat
distribution, and diabetes [1,3,8].
The plasma level of visfatin was associated with type 2
diabetes mellitus, independent of known risk factors, in a
Chinese population [9]. Visfatin levels increased in Asian
Indians with type 2 diabetes mellitus, but the association was
lost after adjusting for obesity [10]. In another study, visfatin
levels were reported to be higher in the diabetic group than the
controls, but there was no significant difference in visfatin
levels between the impaired glucose-tolerant group and the
healthy controls [11]. Visfatin levels were correlated with
HbA1c in patients with type 2 diabetes and lowered by
intensive glycemic control [12]. Higher serum levels of visfatin
in women with gestational diabetes were also reported [13,14].
Plasma visfatin concentration was negatively associated with
vascular endothelial function in type 2 diabetes mellitus [15].
Visfatin was shown to be synthesized in cultured mesangial
cells and to stimulate glucose uptake in glomerular mesangial
cells. Thus, it was hypothesized that visfatin may contribute to
acceleration of diabetic nephropathy through the aggravation
of metabolic alterations [16].
Vaspin (visceral adipose tissue-derived serpin), a member
of the serine protease inhibitor family, is a novel adipocyto-
kine with insulin-sensitizing effects [17]. The circulating level
and tissue expression of vaspin increased at the peak of
obesity and insulin resistance in Otsuka Long–Evans Tokush-
ima fatty (OLETF) rats, an animal model of abdominal obesity
and type 2 diabetes mellitus [18]. It has been suggested that the
compensatory increase in vaspin levels during insulin resis-
tance may ameliorate the action of unknown up-regulated
proteases, which impair the insulin action [18]. However,
circulating vaspin levels in relation to insulin sensitivity/
insulin resistance status and glucose metabolism are con-
flicting and remain to be elucidated.
First-degree relatives of subjects with type 2 diabetes
mellitus (FDRs) frequently have both insulin resistance [19]
and beta cell dysfunction [20] and bear a 40% lifetime risk for
developing type 2 diabetes mellitus [21]. With such a
background of the pathophysiology of glucose metabolism
in FDRs, investigating the circulating levels of novel adipocy-
tokines, such as visfatin and vaspin, in this group is
worthwhile. The present study, for the first time, sought to
explore serum visfatin and vaspin concentrations in FDRs.
2. Methods
2.1. Subjects and physical measurements
A total of 90 glucose-tolerant subjects (41 men, 49 women,
mean age 40.55  9.36 years) of first-degree relatives of Iranian
patients with type 2 diabetes mellitus (FDRs) who consecu-
tively visited the Endocrine Clinic of Fatemeh-Zahra Universi-
ty Hospital were enrolled in this study. We selected an
age- and sex-matched glucose-tolerant control group (49 men,
40 women, mean age 41.375  9.47 years) from the Persian Gulf
Healthy Heart Study participants [22] or subjects with noapparent disease history, who underwent a routine health
checkup at General Clinic of Fatemeh-Zahra University
Hospital. They had no family history of diabetes mellitus,
type 2 diabetes or endocrine disorders, cardiovascular
diseases, or hepatic or renal dysfunction and were not taking
antirheumatic drugs and medications for metabolic diseases.
The participants in the control group had anthropometric
measurements comparable to those of the FDRs (Table 1). All
subjects were asked to fast and to present to the Persian Gulf
Health Research Center between 7:30 and 9:30 a.m., after an
overnight fast. They underwent a 75-g oral glucose tolerance
test (OGTT). The definition of glucose tolerant was a subject
who had a fasting plasma glucose level lower than 110 mg/dl
and a second-hour blood sugar level after oral glucose load
(2 h-OGTT) lower than 140 mg/dl [23].
Blood pressure was assessed twice at the right arm after a
15-min rest in the sitting position, using a standard mercury
sphygmomanometer. Height and weight were measured using
a stadiometer. Heavy outer garments and shoes were removed
before height and weight were measured. Body Mass Index
(BMI) was calculated. Waist circumference was defined at the
midway level between the costal margins and the iliac crests.
Hip circumference was measured at the level of the greater
trochanters.
The study was approved by the medical-ethical committee
of Bushehr University of Medical Sciences.
2.2. Laboratory measurements
A fasting blood sample was taken, all samples were promptly
centrifuged, and sera were separated and kept frozen at 70 8C
Fig. 1 – Serum visfatin and vaspin concentrations in first-
degree relatives of subjects with type 2 diabetes mellitus
(FDRs, n = 90) and healthy controls (n = 89). Data are
means W standard deviation.
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sugars, triglyceride, and cholesterol levels) were carried out
at the Persian Gulf Health Research Center on the day of blood
collection using a Selectra 2 autoanalyzer (Vital Scientific,
Spankeren, the Netherlands). Glucose was assayed with the
enzymatic (glucose oxidase) colorimetric method using a
commercial kit (Pars Azmun Inc., Tehran, Iran). Serum total
cholesterol and HDL (high-density lipoprotein) cholesterol
were measured using cholesterol oxidase phenol aminoanti-
pyrine and triglycerides using the glycerol-3 phosphate
oxidase phenol aminoantipyrine enzymatic method. Serum
LDL (low-density lipoprotein) cholesterol was calculated using
the Friedwald formula; LDL cholesterol was not calculated
when the triglycerides concentration was >400 mg/dl. Insulin
was measured using a commercially available enzyme-linked
immunosorbent assay kit (Insulin ELISA, DRG diagnostics,
Marburg, Germany). The assay sensitivity was 1.76 mIU/ml; the
intra- and interassay coefficients of variance were 1.79–2.6%
and 2.88–5.99%, respectively. Insulin resistance was assessed
by calculating the homeostasis model of assessment
index (HOMA-IR) using the equation: fasting insulin (mIU/
ml)  fasting glucose (mg/dl)/405.
To detect visfatin and vaspin in the serum samples,
commercially (Cat. No. V0523EK and Cat. No. V0712EK,
respectively) available enzyme-linked immunosorbent assay
kits (AdipoGen, Seoul, Korea) were used according to the
manufacturer’s instructions. The assay sensitivity for visfatin
was 0.10 ng/ml; the intra- and interassay coefficients of
variance were 3.8–5.5% and 6.4–9.5%, respectively. The assay
sensitivity for vaspin was 0.012 ng/ml; the intra- and inter-
assay coefficients of variance were 1.3–3.8% and 3.3–9.1%,
respectively.
2.3. Statistical analysis
Normal distribution of the data was controlled with the
Kolmogorov–Smirnov test. Probability values <5% were
considered statistically significant. The significance of the
difference in the results between the two groups was
determined with chi-square analysis using 2  2 contingency
tables. A two-tailed t-test was used to compare the values
across groups in the presence of a normal distribution.
Significant differences were assessed with the Mann–Whitney
U test in the absence of a normal distribution. Multiple linear
regression models were used to assess the association
between adipocytokines (visfatin and vaspin) levels (indepen-
dent variables) and anthropometric, blood pressure measure-
ments, and biochemical variables (each factor was considered
a separate dependent variable in a series of models). Because
the distributions of serum insulin levels and HOMA-IR were
skewed, logarithmically transformed values were used for
statistical analysis. Insulin and HOMA-IR showed normal
distributions after the logarithmic transformations. Binary
logistic regression analysis was used to ascertain the
associations between the visfatin levels and the presence of
FDRs. Sex, age, BMI, systolic and diastolic blood pressures,
glucose levels, HOMA-IR and lipid status parameters were
considered covariates, and the presence of FDRs the depen-
dent variable. Standard or simultaneous (Enter Method) type
of regression analysis was used. All statistical analyses wereperformed using the PASW Statistics GradPack 18 (SPSS Inc.,
Chicago, IL).
3. Results
The general characteristics, including blood pressure and
anthropometric measurements, and the biochemical param-
eters of the study groups are shown in Table 1. There was no
significant difference between the two groups regarding blood
pressure measurements, height, weight, waist and hip
circumferences, waist to hip ratio, and BMI. There was
also no significant difference in the fasting blood glucose,
2 h-OGTT, and lipid profiles between the two groups. However,
the FDRs had higher HOMA-IR and serum insulin levels than
the control group (p < 0.05, Table 1).
Serum visfatin levels were significantly lower in the FDRs
when compared to the controls (1.71  0.93 ng/ml versus
2.69  2.02 ng/ml, p = 0.0001). However, no significant differ-
ence was found in the serum vaspin concentrations between
the FDRs and the controls (0.452  0.254 ng/ml versus
0.409  0.275 ng/ml, p = 0.305; Fig. 1). No gender difference
was found for the circulating visfatin and vaspin levels
(p > 0.05).
There was no significant difference between the FDRs and
control groups regarding the prevalence of consumption of
antihypertensive agents (7.8% versus 4.5%), hypocholester-
olemic drugs (6.7% versus 5.6%) and aspirin (5.6% versus 7.9%).
A total of 10 women in the FDRs group and 13 women in the
control group were on anticontraceptive pills.
Age- and sex-adjusted correlations for serum visfatin and
vaspin in relation to anthropometric, biochemical, and blood
pressure measures are shown in Table 2. Age- and sex-
adjusted serum visfatin concentration levels were significant-
ly correlated with BMI in the FDRs (b = 0.22, p = 0.04). However,
there were no significant correlations between visfatin
concentrations and HOMA-IR, the fasting blood glucose,
2 h-OGTT, triglyceride, total cholesterol, HDL-cholesterol,
LDL-cholesterol, insulin and vaspin levels in the FDRs.
However, age- and sex-adjusted serum visfatin concentration
levels were significantly correlated with total cholesterol
Table 2 – Age- and sex-adjusted correlations for serum visfatin and vaspin in relation to anthropometric, biochemical, and
blood pressure measures in first-degree relatives of subjects with type 2 diabetes mellitus (FDRs) and healthy controls.
Visfatin Vaspin
FDRs Control FDRs Control
b p value b p value b p value b p value
BMI 0.22 0.04 0.13 0.23 0.01 0.93 0.01 0.96
WHR 0.05 0.61 0.15 0.18 0.01 0.94 0.05 0.68
Systolic BP 0.12 0.29 0.04 0.71 0.01 0.91 0.27 0.04
Diastolic BP 0.13 0.25 0.01 0.92 0.04 0.68 0.11 0.37
Fasting glucose 0.04 0.70 0.13 0.23 0.19 0.07 0.05 0.64
2 h-OGTT 0.07 0.48 0.18 0.10 0.05 0.64 0.01 0.93
Triglyceride 0.10 0.38 0.21 0.06 0.10 0.34 0.11 0.36
Total cholesterol 0.07 0.51 0.29 0.01 0.13 0.24 0.01 0.88
LDL-cholesterol 0.05 0.60 0.28 0.01 0.10 0.34 0.03 0.77
HDL-cholesterol 0.08 0.49 0.10 0.39 0.02 0.83 0.08 0.50
Insulin 0.12 0.27 0.02 0.81 0.18 0.12 0.21 0.07
HOMA-IR 0.13 0.24 0.01 0.92 0.25 0.03 0.21 0.07
Visfatin – – – – 0.11 0.30 0.13 0.27
Vaspin 0.11 0.30 0.13 0.27 – – – –
BMI, Body Mass Index; WHR, waist to hip ratio; BP, blood pressure; 2 h-OGTT, second-hour oral glucose tolerance test; HOMA-IR, homeostasis
model of assessment index.
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control group.
Age- and sex-adjusted vaspin was also not correlated with
anthropometric, biochemical, or blood pressure measure-
ments. However, age- and sex-adjusted serum vaspin con-
centration levels were significantly correlated with HOMA-IR
in the FDRs (b = 0.25, p = 0.03).
Table 3 shows unadjusted and adjusted odds ratios (95% CI)
between the presence of FDRs and circulating adipocytokines
levels. In multiple logistic regression analysis, the FDRs
showed a significant association with lower visfatin levels,
even after adjustments were made for age, sex, BMI, and
biochemical parameters [OR = 1.71, CI (1.30–2.25); p < 0.0001].
However, after successive adjustment for potential confoun-
ders, the FDRs did not show a significant association with
vaspin levels (Table 3).
4. Discussion
In the current study, we found that FDRs had a significant
association with lower visfatin levels, even after adjusting for
age, sex, BMI, and biochemical parameters in multivariateTable 3 – Unadjusted and adjusted odds ratios [OR; 95% confid
relatives of subjects with type 2 diabetes mellitus (FDRs) and 
Visfatin 
OR CI 
Unadjusted 1.53 1.22–1.93 
Adjusted for age + sex 1.56 1.23–1.98 
Adjusted for age + sex + BMI 1.60 1.25–2.06 
Adjusted for age + sex + WHR 1.55 1.22–1.96 
Full model 1.71 1.30–2.25 
BMI, Body Mass Index; WHR, waist to hip ratio.
Full model included age, sex, BMI, systolic and diastolic blood pressu
triglyceride, HDL-cholesterol and LDL-cholesterol levels and FDRs (yes vanalyses. However, no significant difference was found in
serum vaspin concentrations between the FDRs and the
controls.
Visfatin shows some insulin mimetic properties [24], and
its molecular mechanism of actions is under vigorous
challenge [4,24,25]. Recently, Brown et al. [26] suggested that
visfatin can significantly regulate insulin secretion, insulin
receptor phosphorylation, and intracellular signaling and
expression of a number of beta cell function-associated genes
in mouse beta cells.
However, there are huge discrepancies in reports of visfatin
in relation to insulin sensitivity and insulin resistance [1,8,13].
Similar to our study, a lack of correlation between circulating
visfatin and insulin/HOMA [27,28] was reported, but in
contrast, a significant correlation between visfatin levels
and insulin/HOMA was observed by other authors [9,13].
Pagano et al. [28] reported that visfatin did not play a role in the
development of insulin resistance, in human obesity, either as
assessed by homeostasis model assessment or during lipid
infusion. The findings of the latter study are in accordance
with the results of other studies that did not find an
association of serum visfatin with insulin resistance
[10,27,29]. Taken together, the current knowledge does notence interval (CI)] between the presence of first-degree
circulating adipocytokines (visfatin and vaspin) levels.
Vaspin
p value OR CI p value
<0.0001 0.53 0.16–1.76 0.304
<0.0001 0.51 0.15–1.73 0.282
<0.0001 0.50 0.14–1.73 0.280
<0.0001 0.51 0.15–1.75 0.287
<0.0001 0.25 0.06–1.06 0.061
res, HOMA-IR, fasting glucose, second-hour blood glucose, insulin,
ersus no).
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development of insulin resistance.
Likewise, visfatin’s relationship with type 2 diabetes
mellitus and its link with pathophysiological pathways in
pre-diabetic states and metabolic syndrome are unclear, and
there is inconsistency in the correlations between circulating
visfatin and diabetes mellitus. In some studies, higher
circulating visfatin levels in patients with type 2 diabetes
mellitus [9,11] and gestational diabetes mellitus [13,14] were
observed while lower levels of visfatin in patients with type 1
diabetes mellitus [30] and gestational diabetes mellitus [31]
were reported. No correlation between visfatin and diabetes
[15] independent of obesity [10] was found in other studies.
Chen et al. [9] suggested that the compensatory elevated
visfatin, which has potential insulin mimetic properties, in
patients with diabetes mellitus, may reflect an impairment of
its action in target tissues, dysregulation in its biosynthesis, or
a response to hyperglycemia/hyperinsulinemia or the altered
state of adipocytokines.
According to the above studies, it appears that frank
impairment conditions of glucose metabolism (e.g., the
diabetes state) are not good models for assessing the
pathophysiological link of visfatin with diabetes mellitus. In
the current study, we evaluated the circulating levels of
visfatin in glucose-tolerant FDRs.
Impaired glucose metabolism is common in FDRs [19].
They also have defects in beta cell function at a time when
they are not hyperglycemic, and this reduction affects
insulin and amylin responses to glucose stimulation [20].
Since both insulin sensitivity and beta cell dysfunction
predict conversion to diabetes [32,33], FDRs are at increased
risk of type 2 diabetes [21]. A recent large population study
[33] showed that beta cell impairment exists in the offspring
of type 2 diabetes patients, even in the absence of insulin
resistance, suggesting that beta cell dysfunction is the
outstanding determinant for the development of diabetes
mellitus in this group.
Revollo et al. [34] provided several lines of evidence that
visfatin (Nampt)-mediated systemic nicotinamide adenine
dinucleotide (NAD) biosynthesis is critical for beta cell
function. Visfatin/Nampt is an important rate-limiting moiety
in the NAD biosynthetic pathway from nicotinamide [35].
Alteration in NAD levels could alter the enzymatic activities of
NDA-dependent deacetylase Sirt1 and affect important meta-
bolic pathways that are essential for regulating glucose-
stimulated insulin secretion in pancreatic beta cells [34].
Revollo et al. [34] showed that visfatin/Nampt+/ mice and
islets had defects in nicotinamide mononucleotide (NMN)/
NAD biosynthesis and glucose-stimulated insulin secretion,
and these defects were corrected by the administration of
NMN, a product of the visfatin reaction.
As a major limitation, beta cell function was not assessed in
the current study. However, based on the results of the above
study [34], we can hypothesize that the observed lower
circulating visfatin levels in our FDRs may lead to derange-
ment in visfatin-mediated systemic NAD biosynthesis and
early defects in glucose-stimulated insulin secretion in their
pancreatic beta cells. Undoubtedly, assessment of beta cell
function and measurement of plasma NMN levels in FDRs
would be helpful.It should be noted that the linking mechanism of low
visfatin levels and early beta cell dysfunction in FDRs appears
not to be operative in the advanced phases of beta cell
deterioration, similar to type 2 diabetes mellitus. In fact,
increasing circulating visfatin levels was demonstrated with
progressive beta cell deterioration [36]. To identify the
pathophysiological stimuli that cause increased production
of visfatin in type 2 diabetes, as reported by some authors,
further investigations are needed.
We found a significant correlation between visfatin levels
and BMI in the FDRs. Circulating visfatin concentration in
relation to obesity is controversial [27,28,37,38]. In a recent
study [39], visfatin/PBEF/Nampt mRNA levels were not
correlated with measures of obesity, and the researchers
suggested that visfatin is not predominantly secreted from
visceral fat.
We found that age- and sex-adjusted serum visfatin
concentration levels were significantly correlated with total
cholesterol and LDL-cholesterol in the control group but this
positive correlation was lost in the FDRs group. It was
suggested that visfatin-induced free fatty acid flux to liver,
drives very low density lipoprotein production, leading to
elevated plasma triglyceride and total cholesterol [39].
However, there are controversies in reports of visfatin in
relation to lipid metabolism. Positive correlations between
visfatin concentrations and total cholesterol [39], HDL-
cholesterol [40,41] and triglyceride levels [39] were observed
by other authors. In contrast, negative correlations between
visfatin concentrations and LDL-cholesterol [40], HDL-
cholesterol and triglyceride [41] levels were reported.
Zahorska-Markiewicz did not observe a correlation between
visfatin concentrations and lipids in both the obese and lean
groups [37]. The lack of correlation between visfatin levels and
parameters of lipid metabolism in the FDRs group warrants
further study.
In our study, there was no difference in circulating vaspin
between the FDRs and the controls. Human vaspin expression
was associated with obesity, insulin resistance, glucose
metabolism in human [42] and insulin sensitivity in rats
[43]. Vaspin levels were reported to be significantly elevated in
nonobese and obese T2DM patients compared with controls
[44]. In another study, there was no significant difference in
circulating vaspin between normal glucose-tolerant subjects
and patients with type 2 diabetes mellitus [45].
Although the association of vaspin levels with insulin
resistance, obesity, and glycemic status is still controversial
in humans [46], it seems that the production of vaspin from
adipose tissue is a compensatory mechanism to ameliorate
severe insulin resistance in obesity and type 2 diabetes
[42,45].
We did not measure insulin sensitivity with the gold-
standard isoglycaemic-hyperinsulinemic clamp test in our
subjects, which is a limitation; however, the FDRs did not
show a significant association with vaspin levels after
adjustments for HOMA-IR in multivariate analysis (Table 3).
Since good correlations between HOMA-IR and insulin resis-
tance assessed by some ‘‘gold standard’’ methods have been
reported [47], we postulate that the level of insulin resistance
in FDRs was not at a threshold to stimulate vaspin secretion, as
a compensatory mechanism.
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cross-sectional, limited inferences can be made regarding
temporality and causation. Another limitation of our study
includes the lack of assessment of beta cell function. Since we
assessed the investigated adipocytokines with single mea-
surements, the changes in these adipocytokines over time
could not be reflected in the current study. To clarify
circulating adipocytokines in relation to worsening of glucose
tolerance over time in FDRs, longitudinal studies are war-
ranted. The measurement of additional adipocytokines and
inflammatory markers and cytokines merits consideration to
elucidate the complex system that regulates beta cell function
and insulin sensitivity in pre-diabetes states.
In conclusion, there was no significant difference in
circulating vaspin levels between the FDRs and the controls.
Therefore, circulating vaspin might not have a determining
value as a biological marker in FDRs. In contrast, the observed
lower circulating visfatin levels in FDRs may suggest a
pathophysiological role for visfatin in beta cell dysfunction
in this group.
Because visfatin-mediated systemic NAD biosynthesis is
vital for beta cell function [34], further studies are needed to
elucidate the precise mechanisms behind underproduction of
visfatin in FDRs to prevent further pathological consequences
including development of type 2 diabetes mellitus in this group.
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